The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, ...

Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price ...

The drug is approved in combination with an aromatase inhibitor as adjuvant therapy for breast cancer patients at high risk of recurrence.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Atrasentan hydrochloride is a small molecule commercialized by Novartis, with a leading Pre-Registration program in IgA Nephropathy (Berger's Disease).

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Returning to Boston this December, the 4th annual Rare & Genetic Kidney Disease Drug Development Summit will unite 30+ experts speakers including Novartis, FDA, XORTX Therapeutics, Walden Biosciences, ...

One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney ...